Neoantigen degradation releases immunogenic neo-peptides on the surface of tumour cells presented by human leukocyte antigen class I (HLA-I) molecules, against which a specific CD8+ T-cell immune response is directed (Figure 1B) [34,51]. This evidence concerns the gene CD8A and neoplasm.